$131 Million is the total value of Asymmetry Capital Management, L.P.'s 32 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 86.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMYRT | Buy | BRISTOL-MYERS SQUIBB-CVRrts | $12,738,000 | +40.6% | 3,558,046 | +49.2% | 9.76% | -1.5% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $10,884,000 | +3.7% | 172,896 | -30.8% | 8.34% | -27.3% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $10,815,000 | +144.5% | 171,316 | +97.9% | 8.29% | +71.3% |
| SAGE | New | SAGE THERAPEUTICS INC | $8,202,000 | – | 197,249 | +100.0% | 6.28% | – |
| GH | Buy | GUARDANT HEALTH INC | $7,792,000 | +46.5% | 96,039 | +25.6% | 5.97% | +2.6% |
| ASND | Buy | ASCENDIS PHARMA A/S - ADRadr | $7,040,000 | +122.0% | 47,599 | +69.0% | 5.39% | +55.5% |
| NSTG | Buy | NANOSTRING TECHNOLOGIES INC | $6,445,000 | +259.7% | 219,577 | +194.7% | 4.94% | +151.9% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $5,296,000 | +134.3% | 159,197 | +91.6% | 4.06% | +64.2% |
| CNC | Buy | CENTENE CORP | $4,919,000 | +407.6% | 77,402 | +374.3% | 3.77% | +255.6% |
| CYTK | Buy | CYTOKINETICS INC | $4,857,000 | +101.7% | 206,086 | +0.9% | 3.72% | +41.3% |
| TXG | Buy | 10X GENOMICS INC-CLASS A | $4,539,000 | +196.1% | 50,819 | +106.6% | 3.48% | +107.4% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCadr | $4,312,000 | – | 533,632 | +100.0% | 3.30% | – |
| UNH | Sell | UNITEDHEALTH GROUP INC | $3,806,000 | -3.5% | 12,904 | -18.4% | 2.92% | -32.4% |
| FATE | Sell | FATE THERAPEUTICS INC | $3,745,000 | +40.4% | 109,165 | -9.1% | 2.87% | -1.6% |
| PTCT | Sell | PTC THERAPEUTICS | $3,740,000 | -16.6% | 73,708 | -26.6% | 2.86% | -41.6% |
| ATRS | New | ANTARES PHARMA INC | $3,573,000 | – | 1,299,202 | +100.0% | 2.74% | – |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $3,540,000 | +20.4% | 234,753 | -26.2% | 2.71% | -15.6% |
| BIO | Sell | BIO-RAD LABORATORIES-A | $2,905,000 | -34.6% | 6,434 | -49.2% | 2.23% | -54.2% |
| BNTX | New | BIONTECH SEadr | $2,578,000 | – | 38,626 | +100.0% | 1.98% | – |
| TWST | Sell | TWIST BIOSCIENCE CORP | $2,416,000 | -36.4% | 53,344 | -57.0% | 1.85% | -55.4% |
| LPTX | New | LEAP THERAPEUTICS INC | $1,883,000 | – | 900,733 | +100.0% | 1.44% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $1,680,000 | – | 100,544 | +100.0% | 1.29% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $1,585,000 | – | 211,063 | +100.0% | 1.21% | – |
| BLUE | New | BLUEBIRD BIO INC | $1,526,000 | – | 25,000 | +100.0% | 1.17% | – |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $1,489,000 | -14.2% | 586,243 | -31.5% | 1.14% | -39.9% |
| GRTS | New | GRITSTONE ONCOLOGY INC | $1,480,000 | – | 222,817 | +100.0% | 1.13% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $1,460,000 | – | 22,608 | +100.0% | 1.12% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $1,264,000 | – | 51,074 | +100.0% | 0.97% | – |
| UBX | New | UNITY BIOTECHNOLOGY INC | $1,043,000 | – | 120,179 | +100.0% | 0.80% | – |
| NXTC | New | NEXTCURE INC | $1,039,000 | – | 48,456 | +100.0% | 0.80% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $1,006,000 | – | 34,652 | +100.0% | 0.77% | – |
| NCNA | Sell | NUCANA PLC-ADRadr | $925,000 | -14.7% | 170,987 | -8.2% | 0.71% | -40.3% |
| XCUR | Exit | EXICURE INC | $0 | – | -106,096 | -100.0% | -0.17% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -762,219 | -100.0% | -1.23% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -92,147 | -100.0% | -1.36% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -85,554 | -100.0% | -1.46% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -15,016 | -100.0% | -1.61% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -32,331 | -100.0% | -1.68% | – |
| VAR | Exit | VARIAN MEDICAL SYSTEMS INC | $0 | – | -17,484 | -100.0% | -1.96% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -32,292 | -100.0% | -2.27% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -72,712 | -100.0% | -3.73% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -54,676 | -100.0% | -5.05% | – |
| BAX | Exit | BAXTER INTERNATIONAL INC | $0 | – | -75,737 | -100.0% | -6.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.